226 related articles for article (PubMed ID: 10584060)
21. Treatment of psoriasis with non-registered fumaric acid esters in The Netherlands: a nationwide survey among Dutch dermatologists.
Fallah Arani S; Balak DM; Neumann HA; Kuipers MV; Thio HB
J Eur Acad Dermatol Venereol; 2014 Jul; 28(7):972-5. PubMed ID: 23822581
[TBL] [Abstract][Full Text] [Related]
22. Progressive multifocal leukoencephalopathy associated with fumaric acid esters treatment in psoriasis patients.
Balak DMW; Hajdarbegovic E; Bramer WM; Neumann HAM; Thio HB
J Eur Acad Dermatol Venereol; 2017 Sep; 31(9):1475-1482. PubMed ID: 28322482
[TBL] [Abstract][Full Text] [Related]
23. Long-term treatment with fumaric acid esters in an 11-year-old male child with psoriasis.
Gerdes S; Domm S; Mrowietz U
Dermatology; 2011; 222(3):198-200. PubMed ID: 21502753
[TBL] [Abstract][Full Text] [Related]
24. Fumaric acid esters in combination with a 6-week course of narrowband ultraviolet B provides an accelerated response compared with fumaric acid esters monotherapy in patients with moderate-to-severe plaque psoriasis: a randomized prospective clinical study.
Tzaneva S; Geroldinger A; Trattner H; Tanew A
Br J Dermatol; 2018 Mar; 178(3):682-688. PubMed ID: 29114862
[TBL] [Abstract][Full Text] [Related]
25. Fumaric acid esters: an alternative systemic treatment for psoriasis.
Ameen M; Russell-Jones R
Clin Exp Dermatol; 1999 Sep; 24(5):361-4. PubMed ID: 10564321
[TBL] [Abstract][Full Text] [Related]
26. Fumaric acid esters in psoriasis and multiple sclerosis.
Zecca C; Caporro M; Adami M; Mainetti C; Gobbi C
Clin Exp Dermatol; 2014 Jun; 39(4):488-91. PubMed ID: 24779791
[TBL] [Abstract][Full Text] [Related]
27. Fumaric acid esters in the management of severe psoriasis.
Brewer L; Rogers S
Clin Exp Dermatol; 2007 May; 32(3):246-9. PubMed ID: 17362235
[TBL] [Abstract][Full Text] [Related]
28. Fumaric acid esters for the treatment of psoriasis in Germany: characterising patients in routine care.
Mrowietz U; Sorbe C; Reich K; Von Kiedrowski R; Weckbecker J; Radtke MA; Rustenbach SJ; Augustin M
Eur J Dermatol; 2020 Feb; 30(1):41-48. PubMed ID: 32250255
[TBL] [Abstract][Full Text] [Related]
29. Addition of an oral histamine antagonist to reduce adverse events associated with fumaric acid esters in the treatment of psoriasis: a randomized double-blind placebo-controlled trial.
Balak DM; Fallah-Arani S; Venema CM; Neumann HA; Thio HB
Br J Dermatol; 2015 Mar; 172(3):754-9. PubMed ID: 25041291
[TBL] [Abstract][Full Text] [Related]
30. Dimethylfumarate for psoriasis: more than a dietary curiosity.
Mrowietz U; Asadullah K
Trends Mol Med; 2005 Jan; 11(1):43-8. PubMed ID: 15649822
[TBL] [Abstract][Full Text] [Related]
31. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients.
Altmeyer PJ; Matthes U; Pawlak F; Hoffmann K; Frosch PJ; Ruppert P; Wassilew SW; Horn T; Kreysel HW; Lutz G
J Am Acad Dermatol; 1994 Jun; 30(6):977-81. PubMed ID: 8188891
[TBL] [Abstract][Full Text] [Related]
32. Fumaric acid esters, their place in the treatment of psoriasis.
Ormerod AD; Mrowietz U
Br J Dermatol; 2004 Apr; 150(4):630-2. PubMed ID: 15099356
[No Abstract] [Full Text] [Related]
33. [Psoriasis therapy with fumaric acid and fumaric acid esters].
Raab W
Z Hautkr; 1984 May; 59(10):671-9. PubMed ID: 6741206
[TBL] [Abstract][Full Text] [Related]
34. Efficacy, effectiveness and safety of fumaric acid esters in the treatment of psoriasis: a systematic review of randomized and observational studies.
Balak DM; Fallah Arani S; Hajdarbegovic E; Hagemans CA; Bramer WM; Thio HB; Neumann HA
Br J Dermatol; 2016 Aug; 175(2):250-62. PubMed ID: 26919824
[TBL] [Abstract][Full Text] [Related]
35. Treatment of severe, recalcitrant, chronic plaque psoriasis with fumaric acid esters: a prospective study.
Wain EM; Darling MI; Pleass RD; Barker JN; Smith CH
Br J Dermatol; 2010 Feb; 162(2):427-34. PubMed ID: 19519838
[TBL] [Abstract][Full Text] [Related]
36. Fumaric acid esters in the management of psoriasis.
Balak DM
Psoriasis (Auckl); 2015; 5():9-23. PubMed ID: 29387578
[TBL] [Abstract][Full Text] [Related]
37. Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial.
Sticherling M; Mrowietz U; Augustin M; Thaçi D; Melzer N; Hentschke C; Kneidl J; Sieder C; Reich K
Br J Dermatol; 2017 Oct; 177(4):1024-1032. PubMed ID: 28580646
[TBL] [Abstract][Full Text] [Related]
38. Regulated genes in psoriatic skin during treatment with fumaric acid esters.
Onderdijk AJ; Balak DM; Baerveldt EM; Florencia EF; Kant M; Laman JD; van IJcken WF; Racz E; de Ridder D; Thio HB; Prens EP
Br J Dermatol; 2014 Oct; 171(4):732-41. PubMed ID: 24852654
[TBL] [Abstract][Full Text] [Related]
39. [Immunomodulation with fumaric acid. Systemic therapy in psoriasis].
Sebók B; Schneider I
Orv Hetil; 2000 Jan; 141(3):129-32. PubMed ID: 10693335
[TBL] [Abstract][Full Text] [Related]
40. Impact of fumaric acid esters on cardiovascular risk factors and depression in psoriasis: a prospective pilot study.
Schmieder A; Poppe M; Hametner C; Meyer-Schraml H; Schaarschmidt ML; Findeisen P; Benoit S; Bauer B; Schmid S; Goebeler M; Goerdt S; Ludwig-Peitsch WK
Arch Dermatol Res; 2015 Jul; 307(5):413-24. PubMed ID: 25648959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
